1. Home
  2. TNGX vs MANH Comparison

TNGX vs MANH Comparison

Compare TNGX & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • MANH
  • Stock Information
  • Founded
  • TNGX 2014
  • MANH 1990
  • Country
  • TNGX United States
  • MANH United States
  • Employees
  • TNGX N/A
  • MANH N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • MANH Computer Software: Prepackaged Software
  • Sector
  • TNGX Health Care
  • MANH Technology
  • Exchange
  • TNGX Nasdaq
  • MANH Nasdaq
  • Market Cap
  • TNGX 351.2M
  • MANH N/A
  • IPO Year
  • TNGX N/A
  • MANH 1998
  • Fundamental
  • Price
  • TNGX $6.01
  • MANH $196.16
  • Analyst Decision
  • TNGX Strong Buy
  • MANH Buy
  • Analyst Count
  • TNGX 6
  • MANH 9
  • Target Price
  • TNGX $12.20
  • MANH $208.88
  • AVG Volume (30 Days)
  • TNGX 2.7M
  • MANH 586.2K
  • Earning Date
  • TNGX 08-06-2025
  • MANH 07-22-2025
  • Dividend Yield
  • TNGX N/A
  • MANH N/A
  • EPS Growth
  • TNGX N/A
  • MANH 14.38
  • EPS
  • TNGX N/A
  • MANH 3.50
  • Revenue
  • TNGX $40,990,000.00
  • MANH $1,050,587,000.00
  • Revenue This Year
  • TNGX N/A
  • MANH $3.90
  • Revenue Next Year
  • TNGX N/A
  • MANH $7.11
  • P/E Ratio
  • TNGX N/A
  • MANH $56.04
  • Revenue Growth
  • TNGX 10.09
  • MANH 9.18
  • 52 Week Low
  • TNGX $1.03
  • MANH $140.81
  • 52 Week High
  • TNGX $12.02
  • MANH $312.60
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 76.36
  • MANH 52.38
  • Support Level
  • TNGX $5.34
  • MANH $194.52
  • Resistance Level
  • TNGX $6.40
  • MANH $204.09
  • Average True Range (ATR)
  • TNGX 0.50
  • MANH 4.40
  • MACD
  • TNGX -0.02
  • MANH 0.03
  • Stochastic Oscillator
  • TNGX 84.08
  • MANH 56.83

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: